Comparative Pharmacology
Head-to-head clinical analysis: NORTREL 0 5 35 28 versus TRI SPRINTEC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORTREL 0 5 35 28 versus TRI SPRINTEC.
NORTREL 0.5/35-28 vs TRI-SPRINTEC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Norethindrone and ethinyl estradiol are a combination hormonal contraceptive. Norethindrone suppresses gonadotropin release (FSH and LH) from the pituitary, inhibiting ovulation. Ethinyl estradiol stabilizes the endometrium and enhances the contraceptive effect by inhibiting gonadotropin secretion.
Combination of ethinyl estradiol and norgestimate suppresses gonadotropin release, inhibiting ovulation, and increases viscosity of cervical mucus to inhibit sperm penetration.
1 tablet orally once daily for 28 days (21 active tablets containing 0.5 mg norethindrone and 35 mcg ethinyl estradiol, followed by 7 placebo tablets).
One tablet (0.035 mg ethinyl estradiol / 0.250 mg norgestimate) orally once daily for 21 days, followed by 7 days of placebo tablets. Repeat cycle.
None Documented
None Documented
Norethindrone: 7.2-9.2 hours; Ethinyl estradiol: 13-27 hours. Clinical context: Steady state reached in 5-7 days; half-life supports once-daily dosing.
Norelgestromin: 28 hours; Ethinyl estradiol: 17 hours. Steady-state achieved within 7 days.
Renal: ~40% as metabolites; Biliary/Fecal: ~60% as metabolites; <5% unchanged.
Renal: 50% (metabolites); Fecal: 35% (eliminated in bile); unchanged drug <1%.
Category C
Category C
Oral Contraceptive
Oral Contraceptive